Supplementary Information

TITLE

Core Transcription Factors, MicroRNAs, And Small Molecules Drive Transdifferentiation Of Human Fibroblasts Towards The Cardiac Cell Lineage

AUTHORS & AFFILIATIONS

Nicolas Christoforou^{1,2,#}, Syandan Chakraborty^{3,#}, Robert D. Kirkton¹, Andrew F. Adler⁴, Russell C. Addis⁵, Kam W. Leong³.

¹Department of Biomedical Engineering, Duke University, Durham, NC, USA

²Department of Biomedical Engineering, Khalifa University, Abu Dhabi, UAE

³Department of Biomedical Engineering, Columbia University, New York, NY, USA

⁴Department of Neurosciences, University of California - San Diego, La Jolla, CA, USA

⁵Phelix Therapeutics, Philadelphia, PA, USA

[#]These authors have equally contributed to this work

CORRESPONDING AUTHORS

<u>Kam W. Leong</u>, Department of Biomedical Engineering, Columbia University, Mail Code 8904, 1210 Amsterdam Avenue, New York, NY, 10027, USA, Phone: +1.212.854.8725, Email: kwl2121@columbia.edu

<u>Nicolas Christoforou</u>, Department of Biomedical Engineering, Khalifa University, P. O. Box 127788, Abu Dhabi, UAE, Phone: +973.2.501.8560, Email: nicolas.christoforou@kustar.ac.ae, and Department of Biomedical Engineering, Duke University, 136 Hudson Hall, Box 90281, Durham, NC, 27708, USA, Email: nc28@duke.edu

Contents:

- 1) Supplementary Figure Legends
- 2) Supplementary Table Legends
- 3) Supplementary Movie Legends
- 4) Supplementary Figures
- 5) **Supplementary Table 2**

Supplementary Figure Legends:

Supplementary Figure 1. Immunofluorescence of control cells. Cells were cultured in the same conditions and for the same amount of time used to derive iCM. (A-F) Negative Control (M2rtTA only), (G-L) Cells transfected only with microRNAs.

Supplementary Figure 2. Immunofluorescence of rat neonatal cardiomyocytes. Cells were cultured in the same conditions and for the same amount of time used to derive iCM. Immunofluorescence for: (A) ACTN2, (B) TNNT2, (C) TNNT2 and GJA1, (D) ACTN2 and SERCA2, (E) RYR2 and TNNT2, (F) TAGLN, (G) ACTA2, (H) MYH11.

Supplementary Figure 3. Gene expression analysis. Relative gene expression analysis performed using RT-PCR on RNA isolated from cells being transdifferentiated for 14 days. Samples: (i) Negative Control, (ii) microRNA only, (iii) cardiac TF only, (iv) microRNA and cardiac TF. \$ denotes significance compared to group i, # denotes significance compared to group ii, % denotes significance compared to group iii (T-Test: \$ or # or % < 0.05).

Supplementary Figure 4. Microarray gene expression analysis. Pathway analysis for genes that were determined to be significantly upregulated or downregulated when comparing iCM (cardiac TF and microRNA) to negative control HDF. Determined using the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt). The "Gene #" column refers to the number of identified genes that belong to a particular pathway and the "P-value" column refers to the P-value of each of the pathways and based on the number of identified genes. C: reference gene number in category, O: number of genes in gene set and category, E: expected number in category, R: enrichment ratio.

Supplementary Figure 5. Microarray gene expression analysis. Comparison of cells transduced with cardiac TF / microRNA and cells transduced only with cardiac TF. (A) Significantly upregulated, and (B) Significantly downregulated genes in iCM (cardiac TF and microRNA) and

compared to cells transduced only with cardiac TF. (C) Pathway analysis for genes that were determined to be significantly upregulated or downregulated when comparing iCM (cardiac TF and microRNA) to cells transduced only with cardiac TF. Determined using the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt). The "Gene #" column refers to the number of identified genes that belong to a particular pathway and the "P-value" column refers to the P-value of each of the pathways and based on the number of identified genes. C: reference gene number in category, O: number of genes in gene set and category, E: expected number in category, R: enrichment ratio.

Supplementary Figure 6. Effect of small molecule inhibitors or protein ligands on the transdifferentiation efficiency of HDF transduced with 5 cardiac TF only. (A-F) Small molecule inhibitor effect and (G-L) protein ligand effect. (A or G) Number of nuclei, (B or H) Number of ACTN2⁺ cells, and (C or I) Number of TNNT2⁺ cells (per mm²). (D or J) Number of Ki67⁺ nuclei normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of TNNT2⁺ cells normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of TNNT2⁺ cells normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of nuclei. (E or K) Number of ACTN2⁺ cells normalized to the total number of nuclei. (F or L) Number of TNNT2⁺ cells normalized to the total number of nuclei. Experiment performed in triplicate. Error bar represents calculated standard deviation. Significant difference between two values was calculated using t-test (two-tailed distribution, two sample unequal variance).

Supplementary Table Legends:

Supplementary Table 1. List of genes that are significantly upregulated or downregulated when comparing transdifferentiated iCM (5 cardiac TF and microRNA) to negative control HDF. Also included is the fold change for the comparison between cells transduced with 5 cardiac TFs and the negative control HDF.

Supplementary Table 2. Primers used for gene expression analysis.

Supplementary Movie Legends:

Supplementary Movie 1. Transdifferentiated iCM transduced with a vector allowing the expression of a genetically encoded calcium indicator (GCaMP3) under the control of the TNNT2 promoter element. Cells are not being stimulated and are just passively being monitored using fluorescence microscopy. The video is presented at 10x acceleration.

Supplementary Movie 2. Transdifferentiated iCM transduced with a vector allowing the expression of a genetically encoded calcium indicator (GCaMP3) under the control of the TNNT2 promoter element. Cells are being stimulated with epinephrine at specific time-points (120 sec: Tyrode's, 180 sec: Epinephrine, 240 sec: Tyrode's, 280 sec: Epinephrine). The video is presented at 10x acceleration.

Supplementary Figures:



Supplementary Figure 1. Immunofluorescence of control cells.



Supplementary Figure 2. Immunofluorescence of rat neonatal cardiomyocytes.



Supplementary Figure 3. Gene expression analysis.

Pathway Commons Analysis: GTMMN+microRNA Versus Negative Control (Upregulated Genes)						
Pathway Description	Entrez Gene	с	ο	Е	R	P-Value
Muscle contraction	7134 10398 7137 10580 7169 1674 25802 88 72 4629 7111 4635 800 4638 462159 7139 4624 7168 7414	45	30	3.37	5.93	1.33E-11
Smooth Muscle Contraction	10398 10580 7169 25802 72 4629 800 4638 59 7168 7414	19	11	1.42	7.73	1.70E-08
Cell junction organization	1002 2318 3728 3655 50848 23705 1006 84612 3909 999 9 459 1012 5584 36881001 1000 51208 56288	60	18	4.49	4.00	2.13E-07
Cell-cell junction organization	1002 3728 50848 23705 1006 84612 999 1012 5584 1001 5 1208 1000 56288	37	13	2.77	4.69	1.41E-06
Striated Muscle Contraction	7134 7137 7169 1674 88 7111 4635 4621 7139 4624 7168	30	11	2.25	4.89	5.70E-06
Endosomal/Vacuolar pathway	3133 3134 3105 3106 3135 3107	9	6	0.67	8.90	1.20E-05
Immunoregulatory interactions between Lymphoid & non-Lymphoid cells	718 3133 3134 10666 3105 1525 3689 3106 999 3688 3135 7412 3107	46	13	3.45	3.77	2.14E-05
Cell-Cell communication	1002 2318 3728 3655 50848 23705 88 1006 84612 3909 99 9 9459 1012 5584 36881001 4684 1000 51208 56288 6709	105	21	2.67	2.67	2.79E-05
Integrin cell surface interactions	8516 3655 50848 3689 5770 999 3679 3912 1280 3690 367 3 3688 7412 3680 3911	66	15	4.94	3.03	8.41E-05
Interferon gamma signaling	3133 3134 3105 3106 5770 2634 3135 2210 7412 3717 310 7 4684	47	12	3.52	3.52	1.00E-04
Interferon Signaling	4599 3133 3134 3437 3105 9636 3433 3106 5770 3690 263 4 3135 2210 3717 74123107 3434 4684	95	18	7.12	2.53	2.00E-04
Adherens junctions interactions	1002 3728 23705 1006 999 1012 1001 1000	25	8	1.87	4.27	3.00E-04
Axon guidance	10398 7223 375790 4651 10486 5604 7430 9723 10570 21 4 785 9037 4629 272895788 3983 286 100133941 998 783 3912 3690 3688 6478 23122 8829 4684 6709	200	28	14.98	1.87	1.00E-03
Interferon alpha/beta signaling	4599 3133 3134 3437 3105 9636 3433 3106 5770 3690 263 4 3135 3434 3107	74	14	5.54	2.53	1.00E-03
Antigen Presentation: Folding, assembly & peptide loading of class I MHC	3133 3134 6890 3105 3106 3135 3107	23	7	1.72	4.06	1.10E-03
Tight junction interactions	50848 84612 5584 51208 56288	12	5	0.90	5.56	1.20E-03
Pathway Commons Analysis: G	MMN+microRNA Versus Negative Co	ontro	ol Do	wnreg	ulated	Genes)
Pathway Description	Entrez Gene	с	0	Е	R	P-Value
Activation of the pre-replicative complex	8318 4173 4175 55388 5558 5427 4174 990 1017 6119 5557	29	11	2.26	4.88	5.57E-06
Biosynthesis of the N-glycan precursor & transfer to a nascent protein	8818 79796 9945 29880 29929 6675 79868 5238 29926	21	9	1.63	5.51	1.25E-05
Post-translational protein modification	5279 79796 9945 29929 5329 79001 29926 5281 4121 811 8818 22872 29880 2677 6675 9695 79868 2530 5238 3998 5277	99	21	7.70	2.73	1.91E-05
G2/M Checkpoints	5984 4175 55388 990 5982 6119 8318 4173 5985 4174 472 1017	40	12	3.11	3.86	3.31E-05
Activation of ATR in response to replication stress	5984 4175 55388 990 5982 6119 8318 4173 5985 4174 1017	34	11	2.64	4.16	3.21E-05
DNA strand elongation	5984 4175 5558 5982 6119 5557 8318 4173 5985 4174	30	10	2.33	4.29	5.50E-05
Pyrimidine metabolism	7371 7084 1890 1633 7372 1806 4907	18	7	1.40	5.00	0.0002
Asparagine N-linked glycosylation	79796 9945 29929 29926 4121 811 8818 22872 29880 6675 9695 79868 2530 5238 3998	67	15	5.21	2.88	0.0002
Synthesis of substrates in N-glycan biosythesis	9945 29926 8818 29880 6675 5238	14	6	1.09	5.51	0.0004
G2/M DNA damage checkpoint	4175 55388 990 8318 4173 4174 472 1017	27	8	2.10	3.81	0.0008

Supplementary Figure 4. Microarray gene expression analysis.



Β

Λ	Gene	Entrez	P-Value	Fold
A	TPM1	Gene 7168	1.7E-04	9.85
	CDC42	998	9.3E-04	9.52
	CELA2A	51032	4.9E-04	7.40
	TPM2	7169	3.5E-05	6.93
	ITGB1	3688	8.9E-02	6.20
	TSPAN8	7103	1.2E-02	5.68
	GKN1 PDLIM7	56287 9260	1.6E-02	5.46
	THBD	7056	2.7E-03	5.03
	TNNI3	7137	1.6E-02	4.83
	TNNC1 KCNB1	/134	5.5E-03 3.9E-04	4.82
	MYH6	4624	1.5E-01	4.31
	PKP4	8502	7.6E-04	4.29
	ACTN2 MICAL2	88 9645	2.8E-04	4.17
	CD36	948	1.5E-02	4.04
	GPX3	2878	3.7E-04	3.95
	CRYM	6236 1428	2.9E-02 4.5E-03	3.94
	TTN	7273	3.3E-02	3.92
	PGAM2	5224	1.5E-03	3.72
	ACE2	1280	4.3E-02	3.66
	HIST1H2BG	8339	9.6E-04	3.46
	MYH6	4624	1.1E-01	3.46
	HCP5 MNDA	10866	6.8E-03	3.46
	MYH3	4621	6.6E-02	3.33
	HIST1H2BC	8339	4.4E-03	3.27
	EPB41L1 LINC00472	2036	2.6E-03	3.21
	HIST2H2BE	8349	3.8E-04	3.15
	CDH8	1006	2.2E-04	3.04
	PLLP NCAM1	51090 4684	3.3E-03	3.02
	GABBR1	2550	1.6E-05	2.95
	SYNPO2L	79933	6.0E-02	2.89
	SIGLEC15 ART4	284266 420	6.9E-06	2.87
	MYOZ2	51778	3.5E-03	2.85
	CDH1	999	1.2E-03	2.83
	OLR1 PPI	4973	3.2E-03 8.3E-04	2.79
	CASQ2	845	2.4E-01	2.69
	GNAS	2778	4.0E-03	2.68
	JMJD6 CELA2B	23210	1.6E-03	2.63
	TNNT2	7139	3.2E-02	2.61
	RCAN2	10231	5.0E-04	2.60
	CLUL1 CYP17A1	1586	3.5E-03	2.59
	CHI3L1	1116	1.2E-02	2.56
	RNF41	10193	6.3E-04	2.55
	RAB40B	10966	2.7E-03	2.53
	HSD3B1	3283	1.0E-01	2.49
	ALDH1A3	220	2.3E-02	2.49
	OPN3	23596	4.3E-02 2.7E-02	2.47
	PALMD	54873	7.3E-03	2.46
	CD24	1E+08	1.6E-01	2.41
	SEPT6	23157	2.6E-03	2.37
	ST6GALNAC5	81849	1.5E-01	2.31
	GPR64	10149	5.6E-02	2.30
	C1orf95	375057	1.0E-02	2.29
	BMP4	652	2.9E-03	2.28
	CALD1 HIST1H4H	800	1.8E-03	2.26
	AQP1	358	3.0E-01	2.25
	HIST1H2AD	3013	3.5E-03	2.23
	ITGB2	83445 3689	1.6E-01 5.9E-02	2.21
	DTNA	1837	2.0E-02	2.17
	FCGR1B	2210	5.1E-02	2.17
	BAMBI	2993	1.0E-03	2.15
	MPZL1	9019	2.5E-03	2.14
	ANKRD1	27063	9.9E-03	2.13
	PLAC8	51316	1.4E-02	2.13
	DES	1674	5.6E-02	2.10
	NECAB2	54550	8.2E-03	2.08
	HTR2B	3357	6.5E-02	2.07
	CLDN18	51208	1.6E-03	2.07
	CLSTN2	64084	4.6E-02	2.06
	PDLIM5	10611	7.8E-03	2.00
	EGLN3	112399	1.5E-03	2.03
	ARL4C	10123	7.1E-04	2.02
	SLC24A3	57419	2.0E-03	2.01
	MEPE	56955	4.2E-03	2.00

Gene	Entrez		Fold
Symbol	Gene	P-Value	Change
MESDO	04004	2.55.02	2.00
WIFSD9	64604	3.5E-03	-2.00
	9706	2.3E-02	-2.00
BIGALNIT	2027	9.4E-02	-2.00
DADED	5037	1.7E-01	-2.03
KAB6B	01762	3.5E-02	-2.04
LT90	23043	4.0E-03	-2.04
FINO	2006	1.1E-01	-2.04
	2201	2.4E-03	-2.04
	1404	0.0E=02	-2.00
MANIAA	4915	2.0E-01	-2.07
	9205	2.1L-02	-2.07
PIPSKID	0010	1.4E-01	-2.00
RABGAPTL	9910	1.1E-02	-2.09
MEAD2	0030	0.5E-02	-2.09
CDNE2	9040	T. TE=02	-2.10
I DDEID4	0208	3.8E-02	-2.11
DZID1	2200	1.2E-02	-2.13
TMEEE4	22013	2.05.02	-2.14
DND	4860	2.0E-02	-2.14
PNP MMD2	4000	2.3E-03	-2.14
NEEM	4314	2.00-01	-2.13
EGE7	2252	5.1E-02	-2.10
	2232 6035	1.7E-03	-2.10
LV75	4065	1.7E-01	-2.10
ATE2	4003	1 9E 02	2.17
TMASEA	407	8.6E-02	-2.10
CDEDI 2	1290	1.0E-03	-2.20
DTDDN2	5700	3.2E.03	2.20
GK	2710	2.7E-02	-2.21
SCPP1	81537	2.7L-02	-2.22
SSYA	6759	1.3E-01	-2.24
V/WA5A	4013	1.3E-01	-2.20
DPYD	1806	2 1E-04	-2.20
PLXNC1	10154	2 1E-02	-2.28
SSX1	6756	1.0E-01	-2.29
STOM	2040	3 1E-03	-2.29
KRT19	3880	2.7E-01	-2.29
DPP4	1803	1 1E-02	-2.30
CETN3	1070	4.6E-04	-2.33
CPD	1362	7.3E-05	-2.36
ARI 6IP1	23204	1.5E-04	-2.37
GPR183	1880	7.7E-02	-2.38
ID4	3400	1.7E-01	-2.40
SV2A	9900	3.9E-04	-2.40
OGN	4969	2.6E-04	-2.43
FAM184A	79632	3.7E-03	-2.44
DIRAS2	54769	3.9E-01	-2.46
B3GNT2	10678	6.4E-03	-2.52
HLA-DPA1	3113	4.8E-03	-2.57
CTNND1	1500	2.2E-04	-2.59
CSPG5	10675	2.3E-02	-2.61
ATP884	79895	2.0L-02	-2.67
CTSK	1513	6.2E-02	-2.02
SPAG1	6674	1.2E-02	-2.09
EDDAA	23071	6.2E-03	-2.09
EKP44 TMASEA	23071	2.75.02	-2.82
1W45F4	/104	2.7E-02	-3.04
SCRG1	2642	4.5E-02	-3.93
GCH1	2643	4.4E-03	-3.99

С

Pathway Analysis: GTMMN microRNA Versus GTMMN Upregulated Genes						
Pathway Name	Entrez Gene	с	0	Е	R	Ρ
Striated Muscle Contraction	7134 7137 7169 1674 4621 7139 88 4624 7168	30	9	0.2	42.14	4.0E-13
Muscle contraction	7134 7137 7169 1674 800 4621 7139 4624 88 7168	45	10	0.3	31.21	5.2E-13
Cell-Cell communication	999 3688 88 4684 51208 1 006	105	6	0.8	8.03	1.0E-04
Smooth Muscle Contraction	7169 800 7168	19	3	0.1	22.18	3.0E-04
Cell junction organization	999 3688 51208 1006	60	4	0.4	9.36	9.0E-04
Integrin cell surface interactions	3689 999 1280 3688	66	4	0.5	8.51	1.2E-03
Cell surface interactions at the vascular wall	3689 4973 3688 7056	70	4	0.5	8.03	1.5E-03
Pathway Analysis: GTMMN microRNA Versus GTMMN Downregulated Genes						
Pathway Name	Entrez Gene	с	ο	Е	R	Ρ
Metabolism of nucleotides	1806 4860	50	2	0.2	9.03	2.1E-02

Supplementary Figure 5. Microarray gene expression analysis.



Supplementary Figure 6. Effect of small molecule inhibitors or protein ligands on the transdifferentiation efficiency of HDF transduced with 5 cardiac TF only.

Gene Symbol	Accession Number	Sequence	Amplimer Size		
TNNT2 NM_000364.2		GGCAGCTGCTGTTCTGAGGGAG	101 bpc		
		TGCCCTGGTCTCCTCGGTCT	Tar pha		
MVUE	NM 002471 2	AGAGGCCCAACGCTCCCTCA	193 bps		
	NIVI_002471.2	GGCGTTCTTCGCCTTGCCCT			
		CCGAGGAGGCGGAGGAGCAA	217 hps		
	NM_000237.2	GCATGGGGCTTTGCTGGCAC	217 005		
MVI 2	NIM 000432.3	TTGCTGCCCTTGGGCGAGTG	273 bps		
	NM_000432.3	GGGGGAAGGCGGCGAACATC			
	NIM 021222.2	AGCCACCAAGCAGGCCCAAC	172 hpc		
	NIM_021223.2	TGGGACACTCACCTTCCCCAGC	172 bps		
CASO2		TCGCCTGCGCCCAGAAGAAAT	205 hpc		
CASUZ	INIVI_001232	CCAGTAGGCAACGAGCAGAGGAA	205 bps		
	NM 006172.2	GGGCCCCTGGGACTCCTCTG	- 115 bps		
NFFA	NIM_006172.3	CCTGTCCATCCTGCCCCCGA			
		ACCTGGAACCTGCAATACTGGAGTAAC	128 bpc		
AIFZAZ	NM_001001.5	CCCCAACATCAGTCATGCACAGGG	120 pps		
SI C2A1		AGTGCCAGACACATTTGCCAGC	120 hno		
SLCOAT	NIVI_001112800	GCGATGGACCAGGCCACACC	i∠9 pps		
DVD2		AGAGCCGAAGTGTGCAGCGG	- 213 bps		
NINZ	NIM_001035.2	CCGCTGGGCCTTGAAGCCAT			
	NM 002667	AACTCCCCAGCTAAACACCCGT	167 hpc		
PLN NIVI_UU2067		ACCAGCAGGACAGGAAGTCTGAA			
MVU11	AGTATCACGGGAGAGCTGGA		217 hps		
	NIVI_002474	ATGTCCTCTCGTCTCTGGCT			
ACT 42	NM 001612	GCCAAGCACTGTCAGGAATC			
		GTCACCCACGTAGCTGTCTT	213 ups		
		AAGGCCAAGTCGAGGGCCAAGA	- 246 hpc		
COLIAI	δ80000 Ινινι	TTTCTTGGTCGGTGGGTGACTCTGA	GA 240 bps		

	NM_000089	AGGGCCAGGGAAACTTTTGCCG	300 bps	
COLTAZ		TCCGGCTGGGCCCTTTCTTACA		
GATA4	NM_002052	TCATCTCACTACGGGCACAG	233 bps	
		GGGAAGAGGGAAGATTACGC		
TBX5	NIM 191796	AAAGAATATCCCGTGGTCCC	291 bps	
	NW_101400	TTCACTGGGTGATGTCTCCA		
MEF2C	NM_002397	ACACCGCCAGCGCTCTTCAC	227 hpc	
		CCTCGTGGCGCGTGTGTTGT	zor ups	
MYOCD	NM 152604	CAAGCCAAAGGTGAAGAAGC	177 bps	
	NW_155004	TAGCTGAATCGGTGTTGCTG		
NKX2-5	NM_004387	CCTCAACAGCTCCCTGACTC	- 201 bps	
		GGGGACAGCTAAGACACCAG		
АСТВ		ACAGAGCCTCGCCTTTGCCGAT		
		CATGCCCACCATCACGCCCTG		

Supplementary Table 2. Primers used for gene expression analysis.